---
pmcid: PMC8526962
image_filename: fonc-11-741326-g004.jpg
figure_link: /pmc/articles/PMC8526962/figure/f4/
number: FigureÂ 4
figure_title: ''
caption: In NSCLC, oncogenes including EGFR, KRAS, and EML4-ALK are activated, while
  tumor-suppressor genes including RAR-beta, RASSF1, p16INK4a and p53 are inactivated.
  In the KEGG MAPK signaling network, the Ras/Raf/MEK/ERK signaling pathway is emphasized
  ().
article_title: 'Everything Old Is New Again: Drug Repurposing Approach for Non-Small
  Cell Lung Cancer Targeting MAPK Signaling Pathway.'
citation: Anisha S. Jain, et al. Front Oncol. 2021;11:741326.

doi: 10.3389/fonc.2021.741326
journal_title: Frontiers in Oncology
journal_nlm_ta: Front Oncol
publisher_name: Frontiers Media S.A.

keywords:
- non-small cell lung cancer
- drug repurposing/repositioning
- MAPK
- targeted therapy
- inhibitors

---
